

X INTERNATIONAL WORKSHOP ON LUNG HEALTH

Respiratory Diseases and
Immune Response

NICE, JANUARY 19 - 21 2023

X IWLH
Hybrid event

Abstract Book

17

UEMS/EACCME Credits

17,5

EBAP Credits
EBAP Mark of Excellence

PCO - Organising Secretariat


**LENA
GROUP**
Your Preferred Partner

Organised by


AFISM
Association Internationale pour la Promotion de Formations
Spécialisées en Médecine et en Sciences Biologiques

Organising Committee:

F. Blasi (Italy)
G. W. Canonica (Italy)
S. Centanni (Italy)
J. C. Virchow (Germany)
T. Welte (Germany)

Scientific Committee:

S. Aliberti (Italy)
J. D. Chalmers (UK)
F. Di Marco (Italy)
E. M. Heffler (Italy)
D. Stolz (Germany)



10TH INTERNATIONAL WORKSHOP ON LUNG HEALTH

NICE

Hybrid Edition

19-21 January 2023

Presidents

Francesco Blasi, Italy
G. Walter Canonica, Italy

Chairmen

Stefani Centanni, Italy
Johann Christian Virchow, Germany
Tobias Welte, Germany

Important note:

*The abstracts in this book are listed in alphabetical order
(First author, last name)*

*The number next to each abstract title correspond to the position in
the IWLH 2023 On site Posters' List*

*The contents of the present booklet cannot be modified, utilized
and/or copied. For more information: info@lung-health.org*



Table of contents

RISING STARS	5
Sex dimorphism contributes to initiation and progression of bleomycin-induced pulmonary fibrosis in mice.....	6
Nintedanib and its outcome among post-COVID pulmonary fibrosis patients residing in high altitude. Case report	7
ABSTRACTS FOR POSTERS	8
12. Sphingosine-1-phosphate signaling as a sexually dimorphic target for asthma treatment.....	9
20. Influence of dose and exposition time in the effectiveness of NAC treatment in human bronchoalveolar basal epithelial cells	10
26. D-dimer levels and response to respiratory support with helmet CPAP in patients with COVID-19 pneumonia	11
16. Blood eosinophil counts as a predictor of COPD exacerbations.....	13
21. TELEMONITORING: improving multidisciplinary care in lung transplanted patients	14
22. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients	17
17. Lung cancer as a comorbidity of Chronic Obstructive Pulmonary Disease (COPD).....	20
18. PREVALENCE OF BRONCHIECTASIS IN COPD PATIENTS	21
11. Neutrophilic inflammation.....	22
1. LTBI (Latent Tuberculosis Infection) mobile screening for refugees in Milan metropolitan area. Efficacy of the intervention	23
2. HUMORAL IMMUNITY AND BRONCHIECTASIS (BE) EXACERBATION RATE (ER)	25
3. Rate of sputum culture conversion on extensive drug resistance treatment TB patients with the backbone regimen of bedaquiline	26
23. CORRELATION OF VARIOUS BIOMARKERS WITH DISEASE SEVERITY IN COVID-19- A PROSPECTIVE COHORT STUDY	27
4. Immunodeficiency in cystic fibrosis and cystic fibrosis-related disease: results from a systematic screening in an adult cohort.....	28
8. Testing at-risk patients for NTM-PD in current clinical practice: results of an international survey.....	29
7. A systematic literature review and meta-analysis of patient risk factors for non-tuberculous mycobacterial pulmonary disease (NTM-PD)	30
19. EFFECTS OF BRONCHODILATION ON FLOW LIMITATION AND ON MORPHOLOGY OF THE LOOP OF SPECIFIC LUNG RESISTANCE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS	32
9. The Hospitalization Burden Among Potentially Treatment-Refractory Nontuberculous Mycobacterial Lung Disease Patients in Japan.....	34
13. Relationship between Asthma Control and Obstructive Sleep Apnea in Vietnamese children with asthma	35



5. TUBERCULOSIS AND ITS PREVALENCE AMONG RESIDENTS RESIDING IN HIGH ALTITUDES OF NEPAL.....36

6. Amikacine Liposome Inhalation Suspension (ALIS) for refractory Mycobacterium Avium Complex (MAC) pulmonary disease: our experience.....37

24. Shunt fraction in Covid-19 related Acute Respiratory Failure39

27. Development and validation of a novel deep learning model for diagnosis of Ventilator-associated pneumonia (AI-VAP).....40

14. Improvement in Health-Related Quality of Life questionnaires with biologic therapies in severe asthma and comorbid chronic rhinosinusitis with or without nasal polyposis: a real-life experience.....42

15. Delineating the molecular mechanism of tslp-driven non type inflammation in SA.....44

28. Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis45

10. Trends in Hospitalizations and Outpatient Visits with Early or Delayed Antibiotic Treatment Initiation in Nontuberculous Mycobacterial Lung Disease46

29. Effects of antiviral therapy on mortality and hospital stay duration in COVID - 19 patients: a retrospective analysis47

25. COVID – 19 in patients with organ transplants.....48



18. PREVALENCE OF BRONCHIECTASIS IN COPD PATIENTS

Daniela Buklioska Ilievska¹; Ivana Mickovski¹; Radmila Neshovska¹; Adriana Buklioska¹; Vesna Trajkova¹; Jordan Minov¹; Sasho Stoleski¹; Dragan Mijakoski¹

¹*Ss. Cyril and Methodius University in Skopje, Skopje, Macedonia (North)*

Introduction - There is increasing recognition that radiological bronchiectasis is present in many patients with COPD. Computed tomography scan images have been used to identify different radiological COPD phenotypes based on the presence and severity of emphysema, bronchial wall thickening, and bronchiectasis. Bronchiectasis is defined as an abnormal dilation of the bronchi, usually as a result of chronic airway inflammation and/or infection. The prevalence of bronchiectasis in patients with COPD is high, especially in advanced stages, estimated prevalence varies from 4% to 50%.

Methods - COPD patients underwent chest CT as part of their clinical assessment. Patients were included if COPD was diagnosed based on spirometry and clinical assessment and excluded if there was clinical bronchiectasis. Scoring was by a simplified system based on Smith (Thorax, 1996) and returned a score of 0 (no bronchiectasis), 1 (0–50% of bronchi involved), or 2 (50–100% of bronchi involved) for each lobe, with a total score of 12 including the lingula; emphysema, interstitial lung disease (ILD), or other pathology was noted. A total of 220 COPD patients (77.2% ex- or current smokers, 79.5% male) were consecutively enrolled.

Results - Bronchiectasis was present in 54.5% of patients (score $\geq 2/12$) and there was significant inter-observer correlation in the scoring ($r=0.63$, $p<0.0001$). Scores were highest in the lower lobes and lowest in the middle lobes (1.66 vs 0.86, $p<0.000$). Patients with widespread bronchiectasis (score $\geq 6/12$) had a trend towards reduced bronchodilator reversibility (4% vs 9%, $p=0.08$) than those with limited bronchiectasis. Emphysema was present in 77.2% and ILD in 11.36%. The overall prevalence of emphysema was not different between patients with and without previous pulmonary tuberculosis (PTB) $n=30$ (13.63%), but in those with previous PTB, a higher number of subjects with middle ($p=0.002$) and lower ($p=0.017$) lobe emphysema, higher severity score ($p=0.029$), higher prevalence of panlobular emphysema ($p=0.015$), and more extensive centrilobular emphysema ($p=0.036$) were observed.

Conclusions - In this study, we found a higher prevalence of bronchiectasis than previously reported which may reflect the heterogeneity of COPD patients in a general respiratory clinic. Radiological features of bronchial wall thickening and mild bronchiectasis were commonly seen and when widespread this may result in reduced bronchodilator reversibility; however, the presence of radiological bronchiectasis was not related to disease severity. COPD patients with previous PTB had unique features of bronchiectasis and emphysema on HRCT, which were associated with significant dyspnea and higher frequency of severe exacerbations.